Vital role for CD8+ cells in controlling retroviral infections.
Antiviral adaptive immune defenses consist of humoral and cell-mediated responses, which together eliminate extracellular and intracellular virus. As most retrovirus-infected individuals do not raise efficient protective antivirus immune responses, the relative importance of humoral and cell-mediated responses in restraining retroviral infection is not well understood. We utilized retrovirus-resistant I/LnJ mice, which control infection with mouse mammary tumor virus (MMTV) and murine leukemia virus (MuLV) via an adaptive immune mechanism, to assess the contribution of cellular responses and virus-neutralizing antibodies (Abs) to the control of retroviral infection. We found that in retrovirus-infected CD8-deficient I/LnJ mice, viral titers exceed the neutralizing capability of antiviral Abs, resulting in augmented virus spread and disease induction. Thus, even in the presence of robust neutralizing Ab responses, CD8-mediated responses are essential for full protection against retroviral infection.
Department of Microbiology, University of Chicago, 920 E. 58th Street, Chicago, IL 60637, USA.
Melissa
M
Kane
Laure K
LK
Case
Tatyana V
TV
Golovkina
D000818:Animals; D057134:Antibodies, Neutralizing / Q000276:immunology; D000914:Antibodies, Viral / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D009052:Leukemia Virus, Murine / Q000276:immunology*; D008324:Mammary Tumor Virus, Mouse / Q000276:immunology*; D051379:Mice; D012192:Retroviridae Infections / Q000276:immunology*
D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral
J Virol. 2006 Mar;80(5):2206-15
16474128
J Infect Dis. 2007 Sep 15;196(6):895-9
17703421
Nat Rev Immunol. 2010 Jan;10(1):11-23
20010788
Curr Opin HIV AIDS. 2009 Sep;4(5):373-9
20048700
Nature. 1991 Feb 7;349(6309):524-6
1846947
PLoS Pathog. 2010 May 27;6(5):e1000917
20523897
Virology. 1993 Nov;197(1):463-7
8212586
Blood. 2006 Jun 15;107(12):4781-9
16467198
Nat Immunol. 2003 Jun;4(6):573-8
12730691
Scand J Immunol. 2000 Mar;51(3):219-23
10736089
Virology. 1993 Mar;193(1):171-85
8382394
J Virol. 1994 Aug;68(8):5019-26
8035502
J Virol. 2008 Feb;82(3):1339-49
18032505
Proc Natl Acad Sci U S A. 1996 May 14;93(10):4589-94
8643448
J Immunol. 2001 Aug 1;167(3):1379-86
11466356
J Virol. 2002 Dec;76(23):12112-22
12414952
Infect Immun. 2007 Sep;75(9):4608-20
17562770
J Virol. 2008 Feb;82(3):1438-47
18057254
Cell. 1982 Nov;31(1):99-109
6297757
J Virol. 2009 Mar;83(6):2743-55
19116253
J Immunol. 2004 May 1;172(9):5582-7
15100301
Scand J Immunol. 1999 Mar;49(3):269-77
10102644
J Virol. 2006 May;80(10):4758-70
16641269
J Gen Virol. 1989 Dec;70 ( Pt 12):3317-25
2514255
Vaccine. 2008 Jun 6;26(24):2981-96
18255203
J Virol. 2000 Mar;74(6):2752-9
10684291
Nat Med. 1999 Feb;5(2):189-93
9930867
J Virol. 1997 May;71(5):3895-903
9094666
Gastroenterology. 2009 Apr;136(4):1391-401
19185579
J Immunol. 2005 Dec 1;175(11):7543-9
16301663
Clin Infect Dis. 2008 Dec 1;47(11):e86-9
18947331
Immunity. 2007 Sep;27(3):406-16
17892849
Nature. 2010 May 20;465(7296):350-4
20445539
J Exp Med. 1991 Dec 1;174(6):1425-9
1683893
Science. 2010 Dec 10;330(6010):1551-7
21051598
J Virol. 1992 Jun;66(6):3271-7
1374804
Trends Pharmacol Sci. 2009 Dec;30(12):631-7
19837464
J Infect Dis. 2009 Sep 15;200(6):984-90
19656066
Virology. 1970 Dec;42(4):1136-9
4099080
Microbes Infect. 2003 Apr;5(5):439-48
12738000
Cell. 1991 May 3;65(3):443-9
1673361
J Virol. 2002 Aug;76(16):7942-8
12133998
J Exp Med. 2003 Jan 20;197(2):233-43
12538662
Nature. 1986 May 15-21;321(6067):239-43
3086743
Nature. 1991 Mar 21;350(6315):203-7
1706480
J Virol. 1999 Aug;73(8):6468-73
10400741
Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6776-81
17428922
J Immunol. 1994 Aug 15;153(4):1553-62
7913941
J Immunol. 1998 Sep 1;161(5):2375-82
9725233
Trends Genet. 1988 Oct;4(10):291-5
3076290
Science. 1999 Apr 30;284(5415):825-9
10221919
AIDS. 2001 Feb;15 Suppl 2:S16-21
11424972